A recent report evaluated paired pre-treatment and relapsed samples from eight adult FLT3-ITD AML patients treated with quizartinib monotherapy, all of which relapsed after initial good marrow responses (161). The gene discussed is FLT3; the disease is acute myeloid leukemia.